Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Insights - Analysts project that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.51 per share, reflecting a year-over-year decline of 16.1% [1] - Revenue is expected to reach $11.83 billion, a slight decrease of 0.5% compared to the same quarter last year [1] Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.6%, indicating a reassessment by covering analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock [3] Key Metrics Forecast - Analysts estimate 'Net Sales- Revlimid' at $707.31 million, down 49.9% year over year [5] - 'Net Sales- Opdivo' is projected at $2.43 billion, showing a 2.8% increase from the previous year [5] - 'Net Sales- Abraxane' is expected to be $95.72 million, down 62.2% from the prior year [5] - 'Net Sales- Reblozyl' is forecasted at $583.06 million, indicating a year-over-year increase of 30.4% [6] - 'Net Sales- Pomalyst/Imnovid- U.S.' is estimated at $573.19 million, down 17.8% year over year [6] - 'Net Sales- Pomalyst/Imnovid- International' is projected at $84.24 million, down 58.1% from the previous year [6] Additional Sales Projections - 'Net Sales- Revlimid- U.S.' is expected to be $617.31 million, down 49.1% year over year [7] - 'Net Sales- Revlimid- International' is projected at $99.33 million, down 50.3% [7] - 'Net Sales- Reblozyl- U.S.' is estimated at $461.95 million, reflecting a 29% increase from the prior year [7] - 'Net Sales- Reblozyl- International' is forecasted at $117.13 million, indicating a 31.6% increase [8] - 'Net Sales- Zeposia- U.S.' is expected to be $95.95 million, down 8.6% year over year [8] - 'Net Sales- Zeposia- International' is projected at $45.74 million, reflecting an 8.9% increase [8] Stock Performance - Over the past month, Bristol Myers shares have returned -0.7%, compared to a +2.5% change in the Zacks S&P 500 composite [9] - Based on its Zacks Rank 3 (Hold), BMY is expected to perform in line with the overall market in the upcoming period [10]